COVID-19: Origin, Impact and Management (Part 1) E-Book
53,95 €
Mehr erfahren.
- Herausgeber: Bentham Science Publishers
- Kategorie: Fachliteratur
- Sprache: Englisch
COVID-19 has spread like wildfire across the globe since the start of the SARS-CoV-2 outbreak, hampering quality of life at multiple levels and causing many deaths. Many aspects of the human experience have been affected, with a body of research being published on its effects on psychological and physical well being, loss of jobs, pay cuts, education, and unpaid caregiving. New findings on these aspects are still emerging as we learn more about the consequences of the pandemic.
This book is intended as a simple summary of recent findings about COVID-19 for academicians and students from science, humanities and commerce backgrounds to understand the pandemic from a microscopic view and how it has touched our lives at different levels.
A collection of topics is presented and explored through chapters dedicated to niche topics on COVID-19. Each chapter is authored by expert scientists, academicians and scholars from leading institutions in India.
The key features of this book set are:
- Interdisciplinary content, making it useful for readers from different academic streams
- A blend of basic and applied research in biology, medicine and social science
- A focus on findings from India
- Updated References for advanced readers
This collection of topics is invaluable for researchers and working professionals in industry and academia as well as general readers who want a broad, insightful perspective on COVID-19.
Das E-Book können Sie in Legimi-Apps oder einer beliebigen App lesen, die das folgende Format unterstützen:
Seitenzahl: 290
Veröffentlichungsjahr: 2009
Ähnliche
BENTHAM SCIENCE PUBLISHERS LTD.
End User License Agreement (for non-institutional, personal use)
This is an agreement between you and Bentham Science Publishers Ltd. Please read this License Agreement carefully before using the ebook/echapter/ejournal (“Work”). Your use of the Work constitutes your agreement to the terms and conditions set forth in this License Agreement. If you do not agree to these terms and conditions then you should not use the Work.
Bentham Science Publishers agrees to grant you a non-exclusive, non-transferable limited license to use the Work subject to and in accordance with the following terms and conditions. This License Agreement is for non-library, personal use only. For a library / institutional / multi user license in respect of the Work, please contact: [email protected].
Usage Rules:
All rights reserved: The Work is the subject of copyright and Bentham Science Publishers either owns the Work (and the copyright in it) or is licensed to distribute the Work. You shall not copy, reproduce, modify, remove, delete, augment, add to, publish, transmit, sell, resell, create derivative works from, or in any way exploit the Work or make the Work available for others to do any of the same, in any form or by any means, in whole or in part, in each case without the prior written permission of Bentham Science Publishers, unless stated otherwise in this License Agreement.You may download a copy of the Work on one occasion to one personal computer (including tablet, laptop, desktop, or other such devices). You may make one back-up copy of the Work to avoid losing it.The unauthorised use or distribution of copyrighted or other proprietary content is illegal and could subject you to liability for substantial money damages. You will be liable for any damage resulting from your misuse of the Work or any violation of this License Agreement, including any infringement by you of copyrights or proprietary rights.Disclaimer:
Bentham Science Publishers does not guarantee that the information in the Work is error-free, or warrant that it will meet your requirements or that access to the Work will be uninterrupted or error-free. The Work is provided "as is" without warranty of any kind, either express or implied or statutory, including, without limitation, implied warranties of merchantability and fitness for a particular purpose. The entire risk as to the results and performance of the Work is assumed by you. No responsibility is assumed by Bentham Science Publishers, its staff, editors and/or authors for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products instruction, advertisements or ideas contained in the Work.
Limitation of Liability:
In no event will Bentham Science Publishers, its staff, editors and/or authors, be liable for any damages, including, without limitation, special, incidental and/or consequential damages and/or damages for lost data and/or profits arising out of (whether directly or indirectly) the use or inability to use the Work. The entire liability of Bentham Science Publishers shall be limited to the amount actually paid by you for the Work.
General:
Any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims) will be governed by and construed in accordance with the laws of Singapore. Each party agrees that the courts of the state of Singapore shall have exclusive jurisdiction to settle any dispute or claim arising out of or in connection with this License Agreement or the Work (including non-contractual disputes or claims).Your rights under this License Agreement will automatically terminate without notice and without the need for a court order if at any point you breach any terms of this License Agreement. In no event will any delay or failure by Bentham Science Publishers in enforcing your compliance with this License Agreement constitute a waiver of any of its rights.You acknowledge that you have read this License Agreement, and agree to be bound by its terms and conditions. To the extent that any other terms and conditions presented on any website of Bentham Science Publishers conflict with, or are inconsistent with, the terms and conditions set out in this License Agreement, you acknowledge that the terms and conditions set out in this License Agreement shall prevail.Bentham Science Publishers Pte. Ltd. 80 Robinson Road #02-00 Singapore 068898 Singapore Email: [email protected]
FOREWORD I
The editors and authors of this book have successfully undertaken a noble and Herculean task to produce a timely guide to the coronavirus (COVID-19) pandemic that is engaging, succinct, and above all, useful to its readers. Unlike many other books about the pandemic, this book brings together experts from different fields from leading Indian and American academic institutions to provide a holistic picture of the origin, impact, and management of one of the worst pandemics humankind has ever had faced.
Such interdisciplinary thinking makes this book unique as it covers not only the science behind the origin of the virus and the development of new vaccines and drugs to fight COVID-19 and its variants but also provides us with the socioeconomic impacts of this deadly pandemic. Even though we have all been impacted by the hardship and heartbreak caused by the pandemic directly or indirectly, this book highlights the heterogeneous effect of the pandemic, particularly on developing economies and women.
I am delighted to see that each chapter in this book is devoted to a different aspect of the COVID-19 pandemic, providing the reader in a single volume with evidence-based research that will help debunk some of the misinformation and disinformation that threaten our understanding of the science behind the disease.
I do not doubt that this book will prove to be an in-depth resource for scientists, academics, researchers, students, and policymakers worldwide for years to come and help us prevent and prepare better for the next pandemic.
FOREWORD II
I feel it a pleasure to write forword to the book entitled “COVID-19: Origin, Impact and Management” edited by Dr Alfred Lawrence & Dr Tahmeena Khan. The SARS-CoV-2 or COVID-19 pandemic has jolted the entire world at different levels. It is not only the health sector that has been greatly impacted, but human life has suffered at multi-levels, be it psychological well being, economic upheaval or discrimination in caregiving at home as faced by women. The education sector also saw reform as online mode took over. The situation is more severe and grim in developing countries and it is very important to find out the vulnerable groups having access to lesser means of protection and prevention.
This innovative book makes for an interesting read as the assorted chapters cater to different aspects related to the pandemic. Several interesting case studies are having an in-depth analysis of the impact of the COVID-19 outbreak on different target groups. The management strategies and vaccines development has also been nicely explained. The inter-disciplinary nature of the book makes it suitable for academicians and students belonging to science, humanities and commerce background. The chapters are very well written and presented in an easy to understand manner.
PREFACE
Since the origin of the SARS-CoV-2 outbreak, the viral disease has spread like wildfire across the entire globe, hampering the quality of human life at multiple levels and causing irretrievable loss of human life. There are many aspects like psychological well-being, loss of jobs, pay cuts, loss of education and unpaid caregiving, emerging as other important consequences of the pandemic. As educators, we need to educate and provide our students with first-hand information about the ongoing crisis. This innovative book is intended to cater to scientists, academicians and students from science, humanities and commerce backgrounds to understand the pandemic from a microscopic view and how it has touched our lives at different levels. The unique special point of this book is its interdisciplinary nature making it useful for people belonging to different academic streams. A collection of topics has been explored through dedicated chapters authored by expert scientists, academicians and research scholars from leading and premier institutions. The chapters range from the very origination of the virus and factors that may facilitate its spread, like air pollution, along with the impact on nutritional, mental, psychological, and educational aspects. Mortality was not only caused by the virus, but problems like domestic violence, job cuts and suicides due to financial crunch also caused loss of lives, and these aspects are being explored by experts. The book would also provide the necessary information about the management strategies to deal with the peril caused by the COVID pandemonium. Another interesting feature of the book is the inclusion of case studies conducted with different groups like women and children to know how their lives were impacted by the pandemic and how they are coping with the situation. Another distinguishing point of the book is that the majority of the authors are women belonging to different educational backgrounds and reputed academic and research institutions. The book will prove to be of use not only to degree students and academicians but will also provide topics of interest to the common person looking to gain survey-based information on the pandemic.
List of Contributors
The Outbreak of COVID-19 Coronavirus and Associated Facts and Factors
Anushka Pandey1,Anju Verma2,Pavan Kumar Nagar2,Tahmeena Khan3,*Abstract
COVID-19 is a global pandemic resulting in devastating impacts that spread through a virus and are even more contagious than influenza, as evident from the frequent reporting of cluster outbreaks. Although the key problem is that the symptoms are often similar to other common illnesses, such outbreaks can be controlled if individuals with initial symptoms are tested, and further contact tracing is done. The concept presented here discusses the order in which symptoms appear to differentiate it from other respiratory disorders, however, this crucial information is mostly missing. To determine the most likely order of detectable symptoms in COVID-19 patients, we apply a Markov Process to a graded partially ordered set based on clinical observations of COVID-19 cases. A comparison was made between the evolution of these symptoms in COVID-19 and influenza, SARS, and MERS to see if they were present differently. Influenza, according to our hypothesis, begins with a cough, whereas COVID-19 and other coronavirus infections begin with a fever. COVID-19, on the other hand, varies from SARS and MERS in terms of the order of gastrointestinal symptoms. As facilities begin to reopen following the 2020 spring outbreak, our findings support the idea that fever should be used to screen for admission and that appropriate clinical practice should include noting the order of symptoms occurrence in COVID-19 along with other diseases. If this type of systemic clinical approach had been routine, the move from a local to a worldwide pandemic might not have happened.
INTRODUCTION
COVID-19
For the initial novel coronavirus-infected pneumonia (NCIP) cases in Wuhan, Hubei Province, China, we analysed the data of the first 425 confirmed cases to determine the epidemiologic characteristics of NCIP. Most avian influenza A (H7N9) cases in mainland China during the spring of 2013 were reported by pneumonia of an unknown aetiology (PUE) surveillance system. For assessing the role of surveillance bias and possible underreporting in the assessment of the epidemiology of subtype H7N9 cases and the effects of poultry market closures, all PUE cases were analysed, which got reported from 2004 to May 3, 2013 [1].
PUE reporting was inconsistent and was biased towards A (H7N9) affected provinces. No evidence was found that the older ages of persons with A (H7N9) resulted from surveillance bias. The decline in PUE cases after poultry market closures indicates outbreak control [2].
On March 31, 2013, China reported the first human infection of the A (H7N9) virus to the WHO, and as of May 3, 2013, a total of 127 cases resulting in 24 deaths had been reported. The median age of the case patients was 62 years, with 71% of them being males [3].
The first COVID-19-reported individuals who showed symptoms as early as 8th December 2019 were among the stallholders of the Wuhan South China Seafood Market, after which it was closed down on Jan 1. After performing the gene sequencing on Jan 10, it was confirmed to be a novel coronavirus, related to the MERS-CoV and SARS-CoV however, its mortality and transmissibility are still unknown, which are likely to differ from the prior ones [4]. A detailed image of the COVID-19 virus is shown in (Fig. 1).
People who got infected and travelled abroad are the carriers of the virus and the initiation of a global outbreak was marked. 13th January 2020 was the first internationally reported case from Thailand outside China [5].
Fig. (1)) Digital image of COVID-19 Virus.On January 22, 2019, the WHO emergency committee discussed whether to declare it a public health emergency of international concern (PHEIC) under health regulations, but went undecided in the absence of full-proof information [6].
On 23rd January 2020, Wuhan suspended all public transport and air travel and placed residents under quarantine. Screening of people in public places, along with the railways and airways places, was extensively carried out globally [7].
Dashboard for Geographic Information Systems (Updated April 27, 2020)
In light of the current public health crisis, we created an interactive web-based dashboard that was hosted by John Hopkins University's Centre for System Science and Engineering (CSSE) for the visualisation and tracking of cases reported in real-time. On 22nd January 2020, it was publicly shared, illustrating the places and the number of recorded COVID cases, deaths, and recoveries, as well as their locations (Fig. 2). This user-friendly application was created for researchers and health authorities to use as a reference tool, as well as to assist the general public in keeping track of the occurrence. Its data is publicly available and is now shown in the ESRI Living Atlas.
As the manual reporting process becomes difficult with the accelerating of cases being reported globally, we decided to embrace it. A semi-automated living data stream strategy was implemented. DXY, an online platform run by members of the Chinese medical community, was our primary data source initially, but then as time went on, we created a series of data sources which included US county and state health departments, national government health departments, and data aggregating websites like Worldometers.info, BNO, and the COVID tracking Project. The CSSE COVID-19 GitHub Repository has all of our sources, and a JHU team is responsible for data protection and revisions [8].
Fig. (2)) Daily cumulative case numbers (starting Jan 22, 2020) reported by the Johns Hopkins University Centre for System Science and Engineering (CSSE), WHO situation reports, and the Chinese Centre for Disease Control and Prevention (Chinese CDC) for within (A) and outside (B) mainland China from different sources [8].TYPES OF VARIANTS
Variants being monitored, variants of worry, variants of interest, and variances of utmost importance are examples of classifications. Some of them appear to spread faster and easier than others, which might also lead to an increase in COVID-19 cases, exerting more load on the medical system and potentially leading to more hospitalisation and fatalities.
Above that, the types are based on the ease with which the variant spreads, the severity of its symptoms, and how it reacts to medications and immunizations.
Variants of Concern in the India & US: Delta Variant
Delta – B.1.617.2
India was the first to report it. It spreads more quickly than other variants, as well as causing more extreme sickness.
CDC released updated guidance on the need for increasing COVID vaccination coverage and also other precautionary measures for fully vaccinated people as well on 27th July 2021 as several studies and new data keeps emerging.
After a decline from January 2021, a significant increase in cases is seen with increases in hospitalization rates around the country. The case rate looks similar to the earlier time when vaccinations weren’t available. Secondly, as from recent CDC, published data and other reports signal that the Delta variant was more infectious and led to increased transmissibility even in some vaccinated individuals. Unpublished surveillance data will also be publicly available in the coming weeks.
Delta, at present, is the predominant variant in the US. As more information will come out and be made available when more data are published, studies will be conducted in the coming weeks. As of now, CDC’s high-level summary is presented below from whatever scientists so far have come to know [9].
Infections and Spread
The Delta form of SARS-CoV-2 is more infectious and spreads faster than other SARS-CoV-2 strains.
Some studies, such as that from Canada and Scotland, suggest it might lead to more severe illness than the earlier variants in unvaccinated people.Non-vaccinated people are more likely to become infected and spread the virus in society, posing a greater risk of transmission. CDC is monitoring regularly to assess whether fully vaccinated people being asymptomatic can transmit the virus.For the cases of earlier variants of COVID-19, when the viral genetic material from the samples was analysed, it was found that the lower amounts of it were found in the fully vaccinated people who got the breakthrough infections than in the unvaccinated ones. For the case of Delta, the amounts found were similar; however, unlike prior variants, the amount of viral material may go down faster in fully vaccinated ones than the unvaccinated ones [9].Vaccine
Preliminary research shows that when fully vaccinated people are diagnosed with the Delta variant, they can transfer the virus to others. However, infections only affect a tiny percentage of people and are very successful in preventing death or severe illness.
Treatments
Almost all variants in the US responded to the treatment of FDA-authorized monoclonal antibody treatments.
Statement from the Centre for Disease Control and Prevention (CDC) on B.1.1.529 (Omicron Variant)
Identified first: South Africa
Immediate release date: 26th November 2021
WHO classified a new variant as a Variant of Concern named Omicron on 26th November 2021. US hasn’t yet identified any case so far inside it though CDC is following up with this new update. Humans are thankful to the South African government and researchers for publicly reporting this to the rest of the world and continuing to share pertinent information with the US Ministry of Health Services and the Centre for Disease Control and Prevention (CDC). We'll keep you updated as we continue to track this development and collaborate with worldwide public health and industrial collaborators to learn more.
CDC recommends preventive measures that people should follow, such as wearing a mask in public places, washing or sanitizing their hands whenever necessary and maintaining physical distance from others. It is advisable to get fully vaccinated, and CDC encourages booster doses for those who are eligible and travellers should follow the proper travel advice from the Centre for Disease Control and Prevention [10].
Update
As more information becomes available, the CDC will publish updates. India has recorded 213 Omicron Cases as of December 22, 2021. India has confirmed 200 cases of Omicron as of December 21, 2021. (Coronavirus). Of 200 cases, 123 cases are active, and the remaining 77 have been discharged or recovered.
In the meantime, Omicron is spreading rapidly, and it could soon account for more than half of COVID-19 cases (2nd December 2021).
The following are the most important details to be aware of:
As new variants emerge, it is important to take necessary precautions to limit the transmission of infection and obtain a vaccination to slow the formation of new variants.Vaccination programmes will reduce severe illness and hospitalization cases along with deaths.All COVID-19 detecting tests will detect all the variants but, can’t say about the infected variant in particular.Why a booster dose of vaccine is required?
In light of the new variant's hazard, WHO recommends that those who receive entire inactivated virus-based vaccines, as well as those who are most immuno-compromised, obtain booster doses.
COVID-19 CASES IN INDIA
Between the 3rd of January 2020 and the 30th of November 2021, the WHO reported 34,587,822 confirmed cases of Covid, with 468,980 deaths. Vaccines were given out in a total of 1,183,573,646 doses until November 22nd, 2021 [6] Table 2. Table 1 summerised the number of cases and deaths reported by the WHO in India according to different states.
MATERIALS AND PROCEDURES
Data Gathering
COVID-19 Discernible Symptoms in Possible Order
Many hospitals have been over-occupied due to an exponential increase in cases in the current pandemic. Those who have the mild form of the disease are advised to seek consultation from their home in isolation. We chose to include these four symptoms in the Stochastic Progression Model because they are similar to those of other respiratory disorders. When the odds for each symptom are uniformly random, the occurrence of symptoms associated was determined first to confirm the model's validity. The most and least likely avenues for the occurrence of the four symptoms are illustrated in the diagram below by red and blue lines, respectively. Each conceivable path is equally likely, with the least and most common pathways describing the most often and least likely set of symptoms that a randomly infected person in the population might suffer [11].
In COVID-19, the Order of Discernible Symptoms is Unrelated to the Severity of the Disease Just at the Time of Admission
We used the Stochastic Progression Model for each group of cases independently after separating the dataset of COVID-19 cases (N= 1099) into severe and non-severe patients as identified during admitting, and investigating the influence of severity on the order of observable symptoms. In both severe and non-severe cases, it was discovered that the most and least likely courses are identical. To highlight these similarities, the most significant variation in likelihood is noted when the most likely path transitions from no symptoms to fever. In severe and non-severe instances, probabilities of 0.775 and 0.818 were found, showing a difference of 0.043 (Fig. 3). All of these findings support the idea that fever is the first symptom of COVID-19 and the order of detectable symptoms is unaffected by severity [12].
Fig. (3)) Illustrates the most and least likely routes of detectable symptoms in COVID-19 instances with severe and non-severe COVID-19. (A) Hasse Diagram representing COVID-19's most likely (red) and least likely (blue) routes for cases classified as severe on admission based on transition probabilities reported here. (B) Hasse Diagram depicting most likely (red) and least likely (blue) COVID-19 routes for cases classified as non-severe on admission based on transition probabilities reported here [13].Variation of Respiratory Disorders & the Order of Observable Symptoms
We used the Stochastic Progression Model to estimate the least and most likely routes for four respiratory diseases: COVID-19, influenza, MERS, and SARS. The four observable symptoms are objective and reasonably easy for physicians and patients to validate. Fever, cough, nausea/vomiting, and diarrhoea are the most common symptoms of COVID-19. It's identical to influenza by reversing the sequence of the first two symptoms listed above. The most likely pathways for MERS and SARS are the same, namely fever, cough, diarrhoea, and eventually nausea/vomiting (Fig. 4).
COVID-19 and MERS have the same least likely path, although influenza is different from the other diseases [13].
Fig. (4)) The most likely and least likely pathways for detecting symptoms in respiratory disorders. (A) A Hasse Diagram depicting the most likely (red) and least likely (blue) routes for COVID-19 symptoms. (B) In a Hasse Diagram for influenza symptoms, the most likely (red) and least likely (blue) routes are shown. (C) In a Hasse Diagram for MERS symptoms, the most likely (red) and least likely (blue) routes are shown. (D) In a Hasse Diagram for SARS symptoms, the most likely (red) and least likely (blue) routes are shown. The most and least likely pathways are computed for each diagram using the transition probabilities indicated on the edges. The sample size (N) and inaccuracy of transition probabilities are also shown [13].
